PRKAA2 and metabolic dysfunction-associated steatotic liver disease: By reducing de novo lipogenesis, activation of hepatic AMPK would be anticipated to slow the progression of NAFLD, decreasing the risk of associated complications, such as NASH, cirrhosis, and hepatocellular carcinoma (Matteoni et al., 1999).